Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers with Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial

Table 1

Demographics, prognostic factors, and extent of disease.

	No. of patients
Age
Median	50
Range	25–73
Gender
Male	12
Female	12
Smoking
Never-smoker	12
Light smoker (<10 pack years)	8
Performance status
EGOG PS 0	5
1	16
2	3
Stage
III B “wet”	1
IV	23
Site(s) of metastatic disease
Bone	17
Pleura and pericardium	11
Distant lung	11
Liver and/or suprarenals	10
Distant lymph nodes and/or soft tissues	6
Brain	2
Number of metastatic sites
1	8
2	4
3 or more	12